ASCO Accepts Akari's AKTX-101 ADC Abstract, Bolstering Potential for KRAS Mutant Tumors
AKTX sits 74% above its 52-week low of $3.25 on elevated volume (27× avg).
Summary
Akari Therapeutics announced the acceptance of an abstract for its lead TROP2-targeting antibody-drug conjugate (ADC), AKTX-101, for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. This marks the company's first ASCO acceptance and provides significant external validation for its novel RNA splicing modulator payload platform, specifically highlighting its potential in treating KRAS mutant tumors. For a micro-cap biotech, this is a material positive development, enhancing the credibility and visibility of AKTX-101 as it progresses towards Phase 1 clinical development by late 2026/early 2027. Investors will be watching for the full publication on May 21, 2026, for further details on the preclinical data.
At the time of this announcement, AKTX was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $3.25 to $63.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.